1. European Medicines Agency (EMEA), Committee for Proprietary Medicinal Products (CPMP), Note for guidance on the investigation of bioavailability and bioequivalence. CPMP/EWP/QWP/1401/98, July 2001.
2. U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products - general considerations. Washington 2003.
3. Voronina T.A. Meksidol: spektr farmakologicheskikh effektov. Zhurn nevrol i psikhiat 2012; 112: 12: 86-90.
4. Sariev A.K. Farmakokinetika proizvodnykh 3-oksipiridina v eksperimente: Avtoref. dis. ... kand. med. nauk. M 1987.
5. Shchul'kin A.V., Yakusheva E.N., Chernykh I.V. Raspredelenie meksidola v strukturakh golovnogo mozga, ego kletochnykh elementakh i subkletochnykh fraktsiyakh. Zhurn nevrol i psikhiat 2014; 114: 8: 69-72.